JP2015508082A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508082A5
JP2015508082A5 JP2014557951A JP2014557951A JP2015508082A5 JP 2015508082 A5 JP2015508082 A5 JP 2015508082A5 JP 2014557951 A JP2014557951 A JP 2014557951A JP 2014557951 A JP2014557951 A JP 2014557951A JP 2015508082 A5 JP2015508082 A5 JP 2015508082A5
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
release oral
release
stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014557951A
Other languages
English (en)
Japanese (ja)
Other versions
JP5914701B2 (ja
JP2015508082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/050125 external-priority patent/WO2013123595A1/en
Publication of JP2015508082A publication Critical patent/JP2015508082A/ja
Publication of JP2015508082A5 publication Critical patent/JP2015508082A5/ja
Application granted granted Critical
Publication of JP5914701B2 publication Critical patent/JP5914701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014557951A 2012-02-22 2013-02-18 ドキシラミンおよびピリドキシン、ならびに/またはその代謝物もしくは塩の製剤 Active JP5914701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601754P 2012-02-22 2012-02-22
US61/601,754 2012-02-22
PCT/CA2013/050125 WO2013123595A1 (en) 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016004380A Division JP2016053092A (ja) 2012-02-22 2016-01-13 ドキシラミンおよびピリドキシン、ならびに/またはその代謝物もしくは塩の製剤

Publications (3)

Publication Number Publication Date
JP2015508082A JP2015508082A (ja) 2015-03-16
JP2015508082A5 true JP2015508082A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-23
JP5914701B2 JP5914701B2 (ja) 2016-05-11

Family

ID=49004884

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014557951A Active JP5914701B2 (ja) 2012-02-22 2013-02-18 ドキシラミンおよびピリドキシン、ならびに/またはその代謝物もしくは塩の製剤
JP2016004380A Pending JP2016053092A (ja) 2012-02-22 2016-01-13 ドキシラミンおよびピリドキシン、ならびに/またはその代謝物もしくは塩の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016004380A Pending JP2016053092A (ja) 2012-02-22 2016-01-13 ドキシラミンおよびピリドキシン、ならびに/またはその代謝物もしくは塩の製剤

Country Status (25)

Country Link
US (3) US9089489B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3326611B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5914701B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101588259B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104136004B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR090126A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013224598B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014020186A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2848798C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014001828A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1123122T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK3326611T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2809713T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1197035A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE052301T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL233644A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT3326611T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX355912B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ627593A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL3326611T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT3326611T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201403931YA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI638657B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY34631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013123595A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1197035A1 (en) 2012-02-22 2015-01-02 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
HUE039131T2 (hu) 2013-07-22 2018-12-28 Duchesnay Inc Hányinger és hányás kezelésére szolgáló készítmény
CN103432126A (zh) * 2013-08-05 2013-12-11 北京阜康仁生物制药科技有限公司 一种治疗孕吐的药物组合物
EP3185856B1 (en) * 2014-08-29 2018-05-23 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2017029573A1 (en) 2015-08-17 2017-02-23 Aequus Pharmaceuticals Inc. Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride
EP3697392B1 (en) 2017-10-17 2023-11-15 Synthon B.V. Tablets comprising tamsulosin and solifenacin
HUE053082T2 (hu) * 2018-09-27 2021-06-28 Inibsa Ginecologia S A Eljárás doxilamin-szukcinát- és piridoxin-hidroklorid-tartalmú, módosított hatóanyag-leadású, több kis egységet tartalmazó, orális adagolási forma elõállítására
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
WO2022254277A1 (en) * 2021-05-31 2022-12-08 Maneesh Pharmaceuticals Ltd Extended release composition and its process for the preparation
AU2021225255B1 (en) * 2021-09-03 2022-06-16 Patel, Mihir MR Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.
WO2024180559A1 (en) * 2023-03-01 2024-09-06 Akums Drugs & Pharmaceuticals Limited A stable tablet-in-tablet composition for nausea vomiting in pregnancy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
EP1191924A4 (en) 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT ADMINISTRATION OF (D-THREO) -METHYLPHENIDATE AND A SECOND STIMULANT OF THE CENTRAL NERVOUS SYSTEM
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US6976982B2 (en) 2001-01-09 2005-12-20 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
ATE505224T1 (de) 2002-08-16 2011-04-15 Microchips Inc Vorrichtung mit kontrollierter abgabe und verfahren
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
ATE424928T1 (de) 2004-09-01 2009-03-15 Microchips Inc Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US9034843B2 (en) 2007-09-14 2015-05-19 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
AU2011236548A1 (en) * 2010-04-07 2012-11-01 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
MX2012015188A (es) * 2010-06-22 2013-05-20 Twi Pharmaceuticals Inc Composiciones de liberacion controlada con efecto de alimentos reducido.
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
HK1197035A1 (en) 2012-02-22 2015-01-02 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting

Similar Documents

Publication Publication Date Title
JP2015508082A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2012505884A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JP2015523407A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2018527392A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ624922A (en) Orally administered corticosteroid compositions
JP2012255026A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2009525343A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
JP2009537538A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
PE20140163A1 (es) Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
JP2009537554A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2013529665A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2009517411A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
JP2010527347A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015510916A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME02474B (me) Terapijski režimi
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
JP2013508289A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2013516493A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2009505991A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12014502609B1 (en) Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
JP2016508996A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)